Postinflammatory hyperpigmentation
Postinflammatory hyperpigmentation est conditio cutaneus aucto pigmento in cute post inflammationem cutis. Postinflammatory hyperpigmentation ex diuturno sole vel nuditate, inflammatione vel aliis cutis iniuriis, etiam quae acne cognatae sunt, causari potest. Homines in cute tonis obscurioribus proniores esse solent ad hyperpigmentationem cum superfluitate solis nuditatis.
☆ In anno 2022 Stiftung Warentest ex Germania provenit, satisfactio consumptoria cum ModelDerm paulo minus fuit quam cum consultationibus telemedicinis solutis.
References
Postinflammatory hyperpigmentation (PIH) Crebra cutis problema, quod post inflammationem cutis aut laesionem fit. Longum tempus tendit et in hominibus obscurioribus tonis cutis est peior (Fitzpatrick skin types III–VI) . Quamvis enim se ipsa saepe convalescat, hoc tamen ad tempus sumere potest, ut saepe diu curatio opus sit. Diversas curationes opera optima componendo.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation communis est sequelae inflammationis cutis. Affectare homines magis ac saepius obscuriores callosos tendit. Studia monstrant quaestiones similes postinflammatory hyperpigmentation esse inter praecipuas causas cur homines cum tonis obscurioribus cutis curam dermatologicam quaerunt. Praemature curatio pendet ad solvendum postinflammatory hyperpigmentation et plerumque incipit cum conditione inflammationis initialis administrandi. Prima linea curationis typice involvit utentes agentibus topicis qui cutem una cum sunscreen ad tutelam illustrant. Haec agentia, sicut hydroquinone, azelaic acid, kojic acid, arbutin, licorice extracts , efficaciter pigmentationem nimiam minuere possunt. Accedit, retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, soy etiam ut agentium depingendorum adhibentur, cum novas curationes emergentes. Cum curationes topicae efficaces solent ad hyperpigmentationem superficiei gradus, rationes (laser, chemical peel) necessariae sunt in causis contumacibus. Gravis est cavere cum his curationibus vitare irritationem et peiorationem verborum postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
